PIK3CA mutation in HPV-associated OPSCC patients receiving deintensified chemoradiation.
PIK3CA is the most frequently mutated gene in HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). Prognostic implications of such mutations remain unknown. We sought to elucidate the clinical significance of PIK3CA mutations in HPV-associated OPSCC patients treated with definitive chemoradiation (CRT). Seventy-seven patients with HPV-associated OPSCC were enrolled on two phase II clinical trials of de-intensified CRT (60 Gy intensity-modulated radiotherapy with concurrent weekly cisplatin). Targeted next-generation sequencing was performed. Nine of 77 patients had disease recurrence (2 regional, 4 distant, 3 regional and distant). Thirty-four patients had mutation(s) identified; 16 had PIK3CA mutations. Patients with wild-type-PIK3CA had statistically significantly higher 3-year disease-free survival than PIK3CA-mutant patients (93.4% [95% CI 85.0-99.9%] vs. 68.8% [95% CI 26.7-89.8%]; p = 0.004. On multivariate analysis, PIK3CA mutation was the only variable statistically significantly associated with disease recurrence (HR 5.71 [95% CI 1.53, 21.3], p = 0.01). PIK3CA mutation is associated with worse disease-free survival in a prospective cohort of newly diagnosed HPV-associated OPSCC patients treated with de-intensified CRT.